NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...
During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...
T-DXd Outranks Treatment of Physicians’ Choice in QOL for HR+/HER2-Low/Ultralow MBC ...
T-DXd Outranks Treatment of Physicians’ Choice in QOL for HR+/HER2-Low/Ultralow MBC ...
The FDA approved amivantamab-vmjw plus chemotherapy for locally advanced or metastatic non–small cell lung cancer (NSCLC) that harbors EGFR exon 19 deletions or exon 21 L858R substitution mutations ...
Nivolumab (Opdivo), when given alone or in combination with ipilimumab (Yervoy), led to significant benefit in 10-year ...
Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine ...
Amivantamab plus chemotherapy delivered promising OS trends compared with chemotherapy in EGFR-mutant advanced non-small cell ...
The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...
While none of the experimental combinations met efficacy targets, durvalumab with monalizumab and ceralasertib showed ...
Experts discuss the adverse events observed with talquetamab, including oral toxicities and skin and nail issues, and how these are managed.
The duo of TAR-200 and cetrelimab was safe and efficacious in the neoadjuvant setting for certain patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback